Please review the CME information below and click the acknowledgment checkbox
at the bottom of the page to begin this activity.
Release Date: February 14, 2011
Expiration Date: February 14, 2012
Target Audience
This educational activity is intended for oncologists and other healthcare providers involved and/or interested in the management of patients with head and neck cancers.
Overview
This brief case discussion discusses the role of human papillomavirus testing and available treatment options for patients with head and neck cancer.
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- • Discuss appropriate management schemes for patients with locally advanced HPV-negative squamous cell carcinoma of the oropharynx, focusing on induction therapy and EGFR inhibition
- • Articulate the importance of HPV status and implications for treatment selection in patients with head and neck cancer
- • Evaluate clinical trial data on the use of combination regimens utilizing anti-EGFR and antiangiogenic agents plus cytotoxic agents as therapeutic options for patients with recurrent/metastatic head and neck cancer
- • Compare and contrast first-line and second-line therapeutic strategies for patients with recurrent/metastatic head and neck cancer
Sponsorship Statement
This activity is sponsored by prIME Oncology.
Accreditation Statement
prIME Oncology is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
prIME Oncology designates this enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be e-mailed to you.
A link to the post-test is available on the Post-Test tabbed page.
Technical Requirements
Estimated time to complete activity: 0.5 hours
Support Statement
This activity is supported Eli Lilly and Company.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, educational activities sponsored by prIME Oncology must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a prIME Oncology–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Dr Khuri has disclosed that he has no real or apparent conflicts of interest to report and no relevant financial relationships with any commercial interests.
The employees of prIME Oncology have disclosed:
- • Janelle Bowersox, RN, MSN, OCN (clinical) – no real or apparent conflicts of interest
- • Heather Tomlinson, MA (editorial) – no real or apparent conflicts of interest
- • Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
- • Susan Yarbrough (compliance) – no real or apparent conflicts of interest
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. prIME Oncology and the supporters of this activity do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturers’ product information, and comparison with recommendations of other authorities.
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the Internet.
